Cargando…
Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment
Patients with Parkinson’s disease and focal dystonia have difficulty in generating and preventing movement. Reaction time (RT) and stop signal reaction time (SSRT) measure the speed to initiate and stop a movement respectively. We developed a portable device to assess RT and SSRT. This incorporated...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925208/ https://www.ncbi.nlm.nih.gov/pubmed/31862983 http://dx.doi.org/10.1038/s41598-019-55321-5 |
_version_ | 1783481870466416640 |
---|---|
author | Choudhury, Supriyo Roy, Akash Mondal, Banashree Singh, Ravi Halder, Saptak Chatterjee, Koustav Baker, Mark R. Kumar, Hrishikesh Baker, Stuart N. |
author_facet | Choudhury, Supriyo Roy, Akash Mondal, Banashree Singh, Ravi Halder, Saptak Chatterjee, Koustav Baker, Mark R. Kumar, Hrishikesh Baker, Stuart N. |
author_sort | Choudhury, Supriyo |
collection | PubMed |
description | Patients with Parkinson’s disease and focal dystonia have difficulty in generating and preventing movement. Reaction time (RT) and stop signal reaction time (SSRT) measure the speed to initiate and stop a movement respectively. We developed a portable device to assess RT and SSRT. This incorporated a novel analysis to measure SSRT more efficiently (optimal combination SSRT, ocSSRT). After validation ocSSRT was measured in Parkinson’s disease patients without dyskinesia (PD), cervical dystonia (CD) and writer’s cramp. We also assessed how ocSSRT responded to L-dopa in PD patients and botulinum toxin injections in CD patients. Participants were instructed to release a button following a green LED flash on the device. On 25% of trials, a red LED flashed 5–195 ms after the green LED; participations were instructed to abort the button release on these trials. ocSSRT and RT were significantly prolonged in patients with Parkinson’s disease and focal dystonia (one-way ANOVA p < 0.001). Administration of L-dopa significantly improved ocSSRT and RT in PD patients (p < 0.001). Administration of botulinum toxin significantly improved ocSSRT, but not RT, in CD patients (p < 0.05). ocSSRT is an easily-administered bedside neuro-physiological tool; significantly prolonged ocSSRT is associated with PD and focal dystonia. |
format | Online Article Text |
id | pubmed-6925208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-69252082019-12-24 Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment Choudhury, Supriyo Roy, Akash Mondal, Banashree Singh, Ravi Halder, Saptak Chatterjee, Koustav Baker, Mark R. Kumar, Hrishikesh Baker, Stuart N. Sci Rep Article Patients with Parkinson’s disease and focal dystonia have difficulty in generating and preventing movement. Reaction time (RT) and stop signal reaction time (SSRT) measure the speed to initiate and stop a movement respectively. We developed a portable device to assess RT and SSRT. This incorporated a novel analysis to measure SSRT more efficiently (optimal combination SSRT, ocSSRT). After validation ocSSRT was measured in Parkinson’s disease patients without dyskinesia (PD), cervical dystonia (CD) and writer’s cramp. We also assessed how ocSSRT responded to L-dopa in PD patients and botulinum toxin injections in CD patients. Participants were instructed to release a button following a green LED flash on the device. On 25% of trials, a red LED flashed 5–195 ms after the green LED; participations were instructed to abort the button release on these trials. ocSSRT and RT were significantly prolonged in patients with Parkinson’s disease and focal dystonia (one-way ANOVA p < 0.001). Administration of L-dopa significantly improved ocSSRT and RT in PD patients (p < 0.001). Administration of botulinum toxin significantly improved ocSSRT, but not RT, in CD patients (p < 0.05). ocSSRT is an easily-administered bedside neuro-physiological tool; significantly prolonged ocSSRT is associated with PD and focal dystonia. Nature Publishing Group UK 2019-12-20 /pmc/articles/PMC6925208/ /pubmed/31862983 http://dx.doi.org/10.1038/s41598-019-55321-5 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Choudhury, Supriyo Roy, Akash Mondal, Banashree Singh, Ravi Halder, Saptak Chatterjee, Koustav Baker, Mark R. Kumar, Hrishikesh Baker, Stuart N. Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment |
title | Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment |
title_full | Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment |
title_fullStr | Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment |
title_full_unstemmed | Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment |
title_short | Slowed Movement Stopping in Parkinson’s Disease and Focal Dystonia is Improved by Standard Treatment |
title_sort | slowed movement stopping in parkinson’s disease and focal dystonia is improved by standard treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925208/ https://www.ncbi.nlm.nih.gov/pubmed/31862983 http://dx.doi.org/10.1038/s41598-019-55321-5 |
work_keys_str_mv | AT choudhurysupriyo slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment AT royakash slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment AT mondalbanashree slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment AT singhravi slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment AT haldersaptak slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment AT chatterjeekoustav slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment AT bakermarkr slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment AT kumarhrishikesh slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment AT bakerstuartn slowedmovementstoppinginparkinsonsdiseaseandfocaldystoniaisimprovedbystandardtreatment |